Thought Leadership In Association With Lachman Consultants 23 Aug 2023 Partnered Content Executive Summary Drug development is undergoing a process of deep digital transformation, with technologies such as artificial intelligence (AI), machine learning (ML), and robotic process automation (RPA) becoming rapidly embedded in operations. Despite the great promise those technologies bring, implementing them often remains a challenge. You may also be interested in… AHPA, CHPA and UNPA say “current statutory definitions already apply to hemp and its extracts and naturally occurring constituents” and “there is no need for a new regulatory pathway to include these ingredients in dietary supplements.” CRN and USHR also assert FDA currently has regulatory tools to allow hemp ingredients’ use in food and supplements. James Jones had 30-year career at the EPA before participating in the Reagan-Udall Foundation’s review of FDA’s food safety programs, reaching deep into agency’s current structural and operational norms to suggest far-reaching changes. The French non-profit, whose IP is incorporated in Zolgensma, is taking its Crigler-Najjar gene therapy into a pivotal study on its own for now. It hopes to be ready for an EU filing in two years. Source: Shutterstock
Click here to view original web page at pink.pharmaintelligence.informa.com
